| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Puma Biotechnology, Inc. (PBYI) has 5 insiders with recent SEC Form 4 filings, including 0 buys and 13 sells. PBYI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 227.5K | $1.81M | - | |
| Other | 70.3K | $559.1K | - | |
| CFO | 66.5K | $529.0K | - | |
| Dir | 54.0K | $429.3K | - | |
| Dir | 41.9K | $332.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 22, 2018 | Eyler Charles R | See Remarks | Sell | 669 | $92.85 | $62,116.65 | -2.3% | |
| Jan 22, 2018 | Bryce Richard Paul | Sr VP, Clinical Research &Dev | Sell | 1,860 | $92.75 | $172,515.00 | -6.8% | |
| Jan 22, 2018 | Auerbach Alan H62 | President And CEO | Sell | 10,692 | $92.75 | $991,683.00 | -0.3% | |
| Dec 1, 2017 | Eyler Charles R | See Remarks | Sell | 1,322 | $105.46 | $139,424.20 | -4.4% | |
| Sep 29, 2017 | Bryce Richard Paul | Sr VP, Clinical Research &Dev | Sale+OE | 15,000 | $120.00 | $1,800,000.00 | -35.5% | |
| Sep 7, 2017 | Bryce Richard Paul | Sr VP, Clinical Research &Dev | Sale+OE | 15,000 | $100.09 | $1,501,400.00 | -21.6% | |
| Jul 20, 2017 | Lo Steven | Chief Commercial Officer | Sell | 1,990 | $94.90 | $188,852.99 | -6.8% | |
| Jul 20, 2017 | Eyler Charles R | See Remarks | Sell | 662 | $95.15 | $62,991.09 | -2.2% | |
| Jul 20, 2017 | Bryce Richard Paul | Sr VP, Clinical Research &Dev | Sell | 1,998 | $94.48 | $188,777.28 | -3.5% | |
| Jul 20, 2017 | Auerbach Alan H62 | President And CEO | Sell | 13,175 | $94.73 | $1,248,005.28 | -0.2% |